Helicobacter Infections Clinical Trial
Official title:
Effectiveness of Rifabutin Triple Therapy for First-line and Rescue Treatment of Helicobacter Pylori Infection
The aim of this study is to determine the effectiveness of rifabutin triple therapy for the treatment of H. pylori infection in the Israeli population. Patients with or without a prior history of H. pylori eradication failure will be randomized to receive one of three possible treatments: Group 1-amoxicillin 1000mg bd and rifabutin 150 mg bd and esomeprazole 40 mg bd Group 2- amoxicillin 1000mg bd and rifabutin 150 mg d and esomeprazole 40 mg bd Group 3- standard of care
Patients who present to the outpatient gastroenterology clinic at our institution with a positive diagnostic test for H pylori will be screened. Included patients will undergo randomisation into 3 groups. Randomization will be performed by a random sequence generator to create equal sized groups in boxes of 12. Group 1-amoxicillin 1000mg bd and rifabutin 150 mg bd and esomeprazole 40 mg bd Group 2- amoxicillin 1000mg bd and rifabutin 150 mg d and esomeprazole 40 mg bd Group 3- standard of care Standard of care in previously untreated patients will consist of concomitant treatment (amoxicillin 1000mg, clarithromycin 500 mg, tinidazole 500 mg and esomeprazole all given twice daily for 14 days). In previously treated patients standard of care will consist of bismuth quadruple therapy, quinolone based therapy, or other susceptibility guided treatment where available. Treatment duration will be 14 days in all groups. Patients who are randomised to Group 3 and fail treatment will be offered open label rescue treatment with amoxicillin 1000mg bd, rifabutin 150 mg bd and esomeprazole 40 mg bd (14 days). ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00723502 -
Efficacy and Safety Study of Finafloxacin Used in Helicobacter Pylori Infected Patients
|
Phase 2 | |
Recruiting |
NCT03365609 -
A Comparison of Four Different Treatment Regimens of Helicobacter Pylori in Chinese Children
|
N/A | |
Completed |
NCT00005496 -
Inflammation, Infection, and Future Cardiovascular Risk
|
N/A | |
Completed |
NCT01219764 -
A Trial of Standard vs Half Dose Rabeprazole, Clarithromycin, Metronidazole and Amoxicillin in the Treatment of Helicobacter Pylori Infection
|
Phase 4 | |
Completed |
NCT00216450 -
Study of the Safety and Effectiveness of Rabeprazole in Treatment of Helicobacter Pylori Infection in Adults.
|
Phase 4 | |
Completed |
NCT00212225 -
Risk Factors for Gastric Disease in Pediatric Helicobacter Pylori (H. Pylori)
|
N/A | |
Completed |
NCT00083291 -
Helicobacter Pylori and Dry Eye
|
N/A | |
Completed |
NCT02449941 -
Helicobacter Pylori and Proton Pump Inhibitor
|
N/A | |
Completed |
NCT02395458 -
Efficacy on Helicobacter Pylori Eradication With Two Antibiotic Regimens
|
Phase 4 | |
Completed |
NCT00194688 -
Breath Ammonia Method for H. Pylori Detection: Phase II
|
Phase 2 | |
Not yet recruiting |
NCT02126722 -
Endofaster Test for Helicobacter Pylori Detection in Patients on Proton Pump Inhibitor Therapy
|
N/A | |
Active, not recruiting |
NCT01133951 -
Helicobacter Pylori Eradication to Prevent Gastric Cancer
|
N/A | |
Completed |
NCT00669955 -
Efficacy and Safety of Quadruple Therapy in Eradication of H. Pylori: A Comparison to Triple Therapy
|
Phase 3 | |
Completed |
NCT00816140 -
Levofloxacin Versus Clarithromycin Triple Therapy in First-Line Treatment for Helicobacter Pylori Eradication
|
Phase 4 | |
Completed |
NCT00490386 -
Helicobacter Pylori and Acute Alcohol Induced Pancreatitis
|
N/A | |
Withdrawn |
NCT02645201 -
The Effect of Probiotic Combination on Helicobacter Pylori Infection in Children
|
N/A | |
Terminated |
NCT00664209 -
Treating H. Pylori in Parkinson's Patients With Motor Fluctuations
|
Phase 3 | |
Completed |
NCT01792700 -
Long-term Follow up Helicobacter Pylori Reinfection Rate After Second-Line Treatment: Bismuth-Containing Quadruple Therapy Versus Moxifloxacin-Based Triple Therapy
|
Phase 4 | |
Completed |
NCT01922505 -
Eradication Rates of Helicobacter Pylori and Its Affecting Factors
|
Phase 4 | |
Completed |
NCT02970110 -
Specimen Collection Study for H. Pylori Testing
|